<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01022190</url>
  </required_header>
  <id_info>
    <org_study_id>A2009-36182</org_study_id>
    <nct_id>NCT01022190</nct_id>
  </id_info>
  <brief_title>Prevention of Heterotopic Ossification With Arcoxia After Total Hip Replacement</brief_title>
  <acronym>Arcoxia</acronym>
  <official_title>Effect of Etoricoxib (Arcoxia) in Preventing Heterotopic Ossification After Total Hip Arthroplasty</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Radboud University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Radboud University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to determine whether Arcoxia is effective in preventing
      heterotopic ossification after total hip arthroplasty.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Rationale: Heterotopic ossification is a frequent complication after total hip replacement.
      Nonsteroidal anti-inflammatory drugs (NSAIDs) are known to effectively prevent heterotopic
      ossification, but gastrointestinal complaints are reported frequently. Selective
      cyclooxygenase-2 (COX-2) inhibiting NSAID produce less gastrointestinal side effects.

      Objective: Preventing heterotopic ossification. Study design: A prospective two-stage study
      design for phase-2 clinical trials with 42 patients to determine if Arcoxia (a COX-2
      inhibitor) 90-mg oral prevents heterotopic ossification. In the first stage, 19-patients are
      included. Another 23-patients are included when at least 90-percent of patients in first
      stage have Brooker classification 0, 1 or 2 at 6-months follow-up.

      Study population: 42-patients with cemented total hip arthroplasty age 18 - 75 yr old.

      Intervention: All subjects receive 90-mg Arcoxia oral for 7-days. Main study
      parameters/endpoints: The main study parameter is the degree of heterotopic ossification
      assessed on AP radiographs using the Brooker classification.

      Nature and extent of the burden and risks associated with participation, benefit and group
      relatedness: No risks are associated with participating into the research. Besides the oral
      intake of Arcoxia, no extra burden is associated with participating in the study. The
      postoperative care does not change. Radiographic examinations will be routinely performed the
      day before surgery, immediately after operation, at 6-weeks and 6-months after surgery. The
      degree of heterotopic ossification will be determined by x-ray assessment.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2009</start_date>
  <completion_date type="Actual">October 2011</completion_date>
  <primary_completion_date type="Actual">October 2011</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants With Heterotopic Ossification (HO) at 6 Months Postoperatively.</measure>
    <time_frame>6 months postoperatively</time_frame>
    <description>Percentage of participants in which Heterotopic Ossification of the hip was assessed, according to the Brooker grade.
Brooker-0): No ossification. Brooker-1): Isolated bone islands, Brooker-2): Bone spurs from the pelvis or proximal femur;space between opposing surface ≥ 1 cm, Brooker-3): Bone spurs from the pelvis or proximal femur;space between opposing surface &lt; 1 cm, Brooker-4): Apparent bony ankylosis. Brooker score 1 to 4 are considered 'heterotopic ossification'.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">42</enrollment>
  <condition>Ossification, Heterotopic</condition>
  <arm_group>
    <arm_group_label>Drug: Etoricoxib (Arcoxia, MSD), 90 mg.</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intervention drug: Etoricoxib (Arcoxia, MSD), 90 mg, orally, one time a day, for a 7 day period.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Etoricoxib (Arcoxia)</intervention_name>
    <description>Oral intake of 90 mg Etoricoxib (Arcoxia) during 7-days</description>
    <arm_group_label>Drug: Etoricoxib (Arcoxia, MSD), 90 mg.</arm_group_label>
    <other_name>Etoricoxib, Arcoxia</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with primary or secondary hip osteoarthritis who are scheduled for cemented
             total hip replacement at the Radboud University Nijmegen Medical Centre, Nijmegen, the
             Netherlands.

          -  Written informed consent is obtained from the patient or the legally accepted
             representative.

        Exclusion Criteria:

          -  Patients with rheumatoid arthritis, ankylosing spondylitis, or femoral neck fractures

          -  Patients with previous allergic reaction on non-steroidal anti-inflammatory drugs

          -  Patients with gastrointestinal complaints at admission, a history of gastrointestinal
             ulcers or perforations, inflammatory bowel-disease, hepatic dysfunction, renal
             dysfunction with a clearance below 30 ml/min and cardiac insufficiency.

          -  Patients with blood pressure consistently &gt; 140/90 mmHg and who have not been
             adequately controlled.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>95 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>R.P.H. Veth, Prof, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Radboud University Nijmegen Medical Centre, department of Orthopedics</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Radboud University Nijmegen Medical Center</name>
      <address>
        <city>Nijmegen</city>
        <zip>6500 HB</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <link>
    <url>http://www.umcn.nl</url>
  </link>
  <reference>
    <citation>van der Heide HJ, Rijnberg WJ, Van Sorge A, Van Kampen A, Schreurs BW. Similar effects of rofecoxib and indomethacin on the incidence of heterotopic ossification after hip arthroplasty. Acta Orthop. 2007 Feb;78(1):90-4.</citation>
    <PMID>17453398</PMID>
  </reference>
  <reference>
    <citation>van der Heide HJ, Koorevaar RC, Lemmens JA, van Kampen A, Schreurs BW. Rofecoxib inhibits heterotopic ossification after total hip arthroplasty. Arch Orthop Trauma Surg. 2007 Sep;127(7):557-61. Epub 2006 Nov 16.</citation>
    <PMID>17106714</PMID>
  </reference>
  <results_reference>
    <citation>Brunnekreef JJ, Hoogervorst P, Ploegmakers MJ, Rijnen WH, Schreurs BW. Is etoricoxib effective in preventing heterotopic ossification after primary total hip arthroplasty? Int Orthop. 2013 Apr;37(4):583-7. doi: 10.1007/s00264-013-1781-0. Epub 2013 Jan 29.</citation>
    <PMID>23359100</PMID>
  </results_reference>
  <verification_date>August 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 27, 2009</study_first_submitted>
  <study_first_submitted_qc>November 30, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 1, 2009</study_first_posted>
  <results_first_submitted>February 8, 2013</results_first_submitted>
  <results_first_submitted_qc>August 30, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">September 2, 2013</results_first_posted>
  <last_update_submitted>August 31, 2013</last_update_submitted>
  <last_update_submitted_qc>August 31, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 9, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Radboud University</investigator_affiliation>
    <investigator_full_name>Jaap Brunnekreef</investigator_full_name>
    <investigator_title>PhD</investigator_title>
  </responsible_party>
  <keyword>Arthroplasty</keyword>
  <keyword>Hip</keyword>
  <keyword>Cemented</keyword>
  <keyword>Heterotopic ossification</keyword>
  <keyword>Selective Cyclooxygenase-2 Inhibitors</keyword>
  <keyword>Arthroplasty, Replacement</keyword>
  <keyword>Hip Prosthesis</keyword>
  <keyword>Cyclooxygenase Inhibitors</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ossification, Heterotopic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Etoricoxib</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>All subjects have been recruited</recruitment_details>
      <pre_assignment_details>No participants were excluded</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Etoricoxib, 90 mg, Orally, Ones a Day</title>
          <description>Patients who underwent total hip arthroplasty were administered Etoricoxib, 90 mg, orally, one a day for a 7 day period to prevent heterotopic ossification of the hip joint after the operation.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="42"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="42"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Etoricoxib</title>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="42"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="54.2" spread="15.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Netherlands</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Heterotopic Ossification (HO) at 6 Months Postoperatively.</title>
        <description>Percentage of participants in which Heterotopic Ossification of the hip was assessed, according to the Brooker grade.
Brooker-0): No ossification. Brooker-1): Isolated bone islands, Brooker-2): Bone spurs from the pelvis or proximal femur;space between opposing surface ≥ 1 cm, Brooker-3): Bone spurs from the pelvis or proximal femur;space between opposing surface &lt; 1 cm, Brooker-4): Apparent bony ankylosis. Brooker score 1 to 4 are considered 'heterotopic ossification'.</description>
        <time_frame>6 months postoperatively</time_frame>
        <population>Patients who underwent total hip arthroplasty and received afterwards Etoricoxib medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Etoricoxib, 90 mg, Orally, One a Day for 7 Days Period</title>
            <description>Etoricoxib, 90 mg, which was administered orally, for a 7-day period to all participants.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Heterotopic Ossification (HO) at 6 Months Postoperatively.</title>
          <description>Percentage of participants in which Heterotopic Ossification of the hip was assessed, according to the Brooker grade.
Brooker-0): No ossification. Brooker-1): Isolated bone islands, Brooker-2): Bone spurs from the pelvis or proximal femur;space between opposing surface ≥ 1 cm, Brooker-3): Bone spurs from the pelvis or proximal femur;space between opposing surface &lt; 1 cm, Brooker-4): Apparent bony ankylosis. Brooker score 1 to 4 are considered 'heterotopic ossification'.</description>
          <population>Patients who underwent total hip arthroplasty and received afterwards Etoricoxib medication.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Etoricoxib</title>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Small sample size. However, due to ethical considerations, a two phase model is necessary to indicate effectivity of Etoricoxib in prevention HO in this phase.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Study director</name_or_title>
      <organization>Radboud University Nijmegen Medical Centre</organization>
      <phone>+31 24 36 13918</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

